Breast Cancer Treatment Studies
60 researchers across 5 institutions
Researchers investigate novel strategies for treating breast cancer, focusing on developing and refining therapeutic approaches. Studies explore a range of treatment modalities, including chemotherapy, targeted therapies, immunotherapy, and hormonal therapies. Investigations delve into understanding drug resistance mechanisms, identifying biomarkers for treatment response, and optimizing drug delivery systems. Preclinical models and clinical trials are employed to evaluate the efficacy and safety of new treatments and treatment combinations. Research also examines the biological underpinnings of breast cancer subtypes to inform personalized treatment plans.
This research holds significant relevance for Arkansas, a state that faces a considerable burden of breast cancer. Understanding and improving treatment outcomes directly addresses public health needs and can lead to better patient care within the state. Efforts to develop more effective and less toxic therapies may reduce healthcare costs and improve the quality of life for Arkansans diagnosed with the disease. Furthermore, advancements in cancer treatment can foster growth in the state's healthcare and biotechnology sectors.
This area of study draws upon expertise in pharmacology, molecular biology, immunology, and health outcomes research. Engagement spans multiple Arkansas institutions, fostering collaborative efforts to advance breast cancer treatment knowledge and application.
Top Researchers
| Name | Institution | h-index | Citations | Career Stage | Badges |
|---|---|---|---|---|---|
| Thomas J. Kelly | UAMS | 90 | 29,523 | High Impact | |
| Mario Schootman | University of Arkansas | 56 | 13,684 | Grant PI High Impact | |
| Laura F. Hutchins | UAMS | 44 | 9,641 | High Impact | |
| Ying Zhong | UAMS | 36 | 4,759 | ||
| Timothy C. Chambers | UAMS | 35 | 4,667 | High Impact | |
| Ronda Henry‐Tillman | UAMS | 30 | 2,974 | High Impact | |
| Magda El‐Shenawee | University of Arkansas | 28 | 2,650 | Grant PI High Impact | |
| Holly C. Felix | UAMS | 20 | 1,820 | High Impact | |
| César Sánchez | UAMS | 20 | 2,449 | High Impact | |
| Varsha Karunakaran | University of Arkansas | 16 | 787 | ||
| Fariba Jousheghany | UAMS | 14 | 691 | ||
| Erin M. Taylor | UAMS | 14 | 736 | ||
| Landry K. Kamdem | Harding University Main Campus | 14 | 1,167 | ||
| Julie A. Wallace | UAMS | 14 | 1,826 | ||
| Laura Adkins | UAMS | 12 | 942 | ||
| Pearman D. Parker | UAMS | 9 | 480 | ||
| Daniela Ochoa | UAMS | 8 | 419 | ||
| Yoshie Sakamaki | University of Arkansas | 8 | 232 | ||
| Faysal Fedda | UAMS | 8 | 277 | ||
| C. Barone | UAMS | 8 | 521 |
Related Research Areas
Connected Research Areas
Topics that share active collaborators with Breast Cancer Treatment Studies in Arkansas. Pairs are ranked by collaboration density relative to expected co-authorship under a random null. This describes existing connections, not investment recommendations.
Strategic Outlook
Global signals from OpenAlex for this research area: where the field is growing, how concentrated leadership is, and where Arkansas sits relative to the world's top-100 institutions. Descriptive only — surfaced as input to the conversation about where to place bets, not a recommendation. Signal confidence: LOW
Top US institutions in this area
- 1 The University of Texas MD Anderson Cancer Center 4,576
- 2 Memorial Sloan Kettering Cancer Center 3,397
- 3 Harvard University 2,606
- 4 Dana-Farber Cancer Institute 2,419
- 5 Massachusetts General Hospital 1,529
Cross-Institution Connections
Researchers at different institutions with overlapping expertise in Breast Cancer Treatment Studies.